---
created: 2025-04-13
updated: 2025-04-13T10:52
id: hD-;sb[^>S
specialty: hemato
specialty_id: 150
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/amboss::hematonco
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::02-platelet-activation
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::07-anticoagulants
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::03-toxicities-&-side-effects::05-drug-reactions---hematologic
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::02-unfractionated-heparin
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::05-hematology-oncology::09-thrombocytopenia
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::heparin-lmwh-fondaparinux
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::10-heme::heparin
  - "source/ak-step1-v11:": 
  - theme/sketchypath::09-blood-&-coagulation::03-coagulopathies-&-platelet-disorders::01-quantitative-platelet-disorders
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::03-blood-&-inflammation::01-anticoagulants-&-thrombolytics::01-heparin,-lmwh,-fondaparinux,-direct-thrombin-inhibitors,-xa-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15120
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step2-v11::!shelf::im::no-dupes
  - source/ak-step2-v11::!shelf::surgery::no-dupes
  - "source/ak-step2-v11:": 
  - theme/amboss
  - "source/ak-step2-v11:": 
  - theme/amboss::surgery
  - "source/ak-step2-v11:": 
  - theme/ome::05-heme-onc::09-thrombocytopenia
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::emma
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::ome::heme/onc::thrombocytopenia
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::uw::heme/onc::heme/onc-dorian
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::uw::heme/onc::heme/onc-zanki
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::surgery::devirgilio-dorian::surgical-cxs
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::surgery::emma
  - source/ak-step2-v11::original-decks::dorian::im::emma
  - source/ak-step2-v11::original-decks::dorian::im::ome::heme/onc::thrombocytopenia
  - source/ak-step2-v11::original-decks::dorian::im::uw::heme/onc
  - source/ak-step2-v11::original-decks::dorian::surg::devirgilio::surgical-cxs
  - source/ak-step2-v11::original-decks::dorian::surg::emma
  - source/ak-step2-v11::original-decks::zanki-step-2::im::hemeonc"
type: flashcard
---

# Question
What is the cause of a hypercoagulable state in a patient on heparin therapy?   **Heparin-induced thrombocytopenia (HIT)**

---

# Answer
due to IgG antibodies against heparin-platelet factor IV complexes which activate the platelets to cause thrombosis.